Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Active-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

NCT07564726 is registered in ClinicalTrials.gov with Celltrion Pharm, Inc. as lead sponsor.

NCT NCT07564726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07564726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Active-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
Lead sponsor
Celltrion Pharm, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 5, 2022
Completion date
February 13, 2024
Enrollment
163 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia, hypertension